Recce Pharmaceuticals Ltd. announced it completed cohort dosing of healthy male and female subjects in its Phase I/II clinical trial evaluating its lead anti-infective candidate, RECCE® 327 (R327), at faster infusion rates. R327 is being developed as a potential treatment for urinary tract infections (UTIs), which, if left untreated, may lead to sepsis, defined as ?urosepsis.? R327 was shown to be safe and well-tolerated at a faster infusion rate of 30 minutes of 3,000mg, with an Independent Safety Committee reviewing the complete cohort data, expected to recommend go ahead, with recruitment well underway.

The Phase I/II trial is evaluating the safety, pharmacokinetics, and pharmacodynamics of R327 following various intravenous doses and infusion rates in healthy subjects.